WO2005014825A3 - Methods of protein production in yeast - Google Patents

Methods of protein production in yeast Download PDF

Info

Publication number
WO2005014825A3
WO2005014825A3 PCT/US2004/025983 US2004025983W WO2005014825A3 WO 2005014825 A3 WO2005014825 A3 WO 2005014825A3 US 2004025983 W US2004025983 W US 2004025983W WO 2005014825 A3 WO2005014825 A3 WO 2005014825A3
Authority
WO
WIPO (PCT)
Prior art keywords
yeast
methods
polynucleotide
host cells
protein production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/025983
Other languages
French (fr)
Other versions
WO2005014825A2 (en
Inventor
Philip J Barr
Helen L Gibson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arriva Pharmaceuticals Inc
Original Assignee
Arriva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arriva Pharmaceuticals Inc filed Critical Arriva Pharmaceuticals Inc
Priority to CA002534352A priority Critical patent/CA2534352A1/en
Priority to EP04780765A priority patent/EP1660661A2/en
Priority to AU2004263900A priority patent/AU2004263900A1/en
Publication of WO2005014825A2 publication Critical patent/WO2005014825A2/en
Publication of WO2005014825A3 publication Critical patent/WO2005014825A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Vectors, host cells, and methods are provided for the production of proteins in yeast. The vectors generally contain a selection gene, a yeast 2 micron sequence, and a polynucleotide encoding a polypeptide, where the polynucleotide is operably linked to promoter, and where the polynucleotide contains one or more yeast-preferred codons. Host cells are cultured under conditions where, after an initial batch phase, oxygen concentration is kept high and glucose feed is regulated so that the yeast cells stay in respiratory metabolism.
PCT/US2004/025983 2003-08-08 2004-08-09 Methods of protein production in yeast Ceased WO2005014825A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002534352A CA2534352A1 (en) 2003-08-08 2004-08-09 Methods of protein production in yeast
EP04780765A EP1660661A2 (en) 2003-08-08 2004-08-09 Methods of protein production in yeast
AU2004263900A AU2004263900A1 (en) 2003-08-08 2004-08-09 Methods of protein production in yeast

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49398403P 2003-08-08 2003-08-08
US60/493,984 2003-08-08

Publications (2)

Publication Number Publication Date
WO2005014825A2 WO2005014825A2 (en) 2005-02-17
WO2005014825A3 true WO2005014825A3 (en) 2005-09-22

Family

ID=34135307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/025983 Ceased WO2005014825A2 (en) 2003-08-08 2004-08-09 Methods of protein production in yeast

Country Status (5)

Country Link
US (2) US7419801B2 (en)
EP (2) EP2287326A1 (en)
AU (1) AU2004263900A1 (en)
CA (1) CA2534352A1 (en)
WO (1) WO2005014825A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172646A1 (en) 2006-05-26 2011-07-28 Amyris Biotechnologies Inc Production of isoprenoids
DK2066778T3 (en) 2006-09-26 2016-04-18 Amyris Biotechnologies Inc PREPARATION OF ISOPRENOIDS AND ISOPRENOID PRECURSORS
TWI368624B (en) * 2007-10-29 2012-07-21 Ind Tech Res Inst Coplymer and method for manufacturing the same and packaging material utilizing the same
JP5727459B2 (en) * 2009-04-22 2015-06-03 アルテオゼン， インクＡｌｔｅｏｇｅｎ， Ｉｎｃ Protein or peptide fusion with increased half-life in the body by maintaining body persistence
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US20120088271A1 (en) * 2010-09-30 2012-04-12 Codexis, Inc. Use of an Endogenous 2-Micron Yeast Plasmid for Gene Over Expression
NZ727213A (en) 2012-03-09 2020-03-27 Vestaron Corp Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides
KR20150093775A (en) * 2012-12-07 2015-08-18 노쓰 캐롤라이나 스테이트 유니버시티 Beta-hexosyl-transferases and uses thereof
AR097805A1 (en) 2013-03-15 2016-04-20 Alder Biopharmaceuticals Inc TEMPERATURE CHANGE CELLS FOR THE EXPRESSION OF HIGH PERFORMANCE OF YEAST POLYPEPTIDES AND OTHER TRANSFORMED
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP2018093806A (en) * 2016-12-14 2018-06-21 国立大学法人山口大学 Methods for overexpressing proteins in yeast
WO2019177982A1 (en) * 2018-03-12 2019-09-19 Protease Pharmaceuticals Inc. Methods and compostions for alpha-1 antitrypsin related disease disorders
CA3117961A1 (en) 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
JP2023507575A (en) 2019-12-20 2023-02-24 コデクシス， インコーポレイテッド Engineered acid alpha-glucosidase variants
JP2023522947A (en) 2020-04-20 2023-06-01 ヴェスタロン・コーポレーション Proteolytically Stable U1-Agatoxin-TA1B Variant Polypeptides for Pest Control
IL297738A (en) 2020-05-01 2022-12-01 Vestaron Corp Insecticide combinations
WO2022067214A2 (en) 2020-09-28 2022-03-31 Vestaron Corporation Mu-diguetoxin-dc1a variant polypeptides for pest control
CN112932460B (en) * 2021-02-01 2022-11-04 重庆大学 Respiratory rate monitoring device and method
US20250188136A1 (en) 2021-04-01 2025-06-12 Vestaron Corporation Av3 mutant polypeptides for pest control
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method
EP4499673A1 (en) 2022-03-30 2025-02-05 Vestaron Corporation Combinations of av3 mutant polypeptides and bt toxins for pest control
US20260013513A1 (en) 2022-05-18 2026-01-15 Vestaron Corporation Pesticidal actx peptide variants
WO2023245100A1 (en) 2022-06-17 2023-12-21 Vestaron Corporation Antimicrobial ncr13 variant peptides
WO2024026406A2 (en) 2022-07-29 2024-02-01 Vestaron Corporation Next Generation ACTX Peptides
WO2024259306A2 (en) 2023-06-16 2024-12-19 Vestaron Corporation Pvd1 variant polypeptides for pest control
WO2025226701A1 (en) 2024-04-23 2025-10-30 Vestaron Corporation Proteolytically stable u1-agatoxin-ta1b variant polypeptides for pest control

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284044A1 (en) * 1987-03-23 1988-09-28 Zymogenetics, Inc. High level expression in yeast
US6068994A (en) * 1989-08-07 2000-05-30 Chiron Corporation Ubiquitin expression system
WO2002050287A2 (en) * 2000-12-18 2002-06-27 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150071A (en) * 1977-08-26 1979-04-17 Respiratory Care, Inc. Nebulizer
IT1105653B (en) * 1978-06-20 1985-11-04 Craighero Margherita AEROSOLIZER APPARATUS
US4253468A (en) * 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
US4198969A (en) * 1978-10-06 1980-04-22 Baxter Travenol Laboratories, Inc. Suction-operated nebulizer
US4453542A (en) * 1980-12-08 1984-06-12 Vortran Corporation Vortex-generating medical products
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
JPS5840733A (en) 1981-09-02 1983-03-09 Toshiba Corp Molding method of mask for color picture tube
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4491228A (en) 1982-06-30 1985-01-01 Fmc Corporation Floating sheave type pendant pay-out system for pendant supported boom
US4599311A (en) * 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US5218091A (en) * 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
DE3480006D1 (en) 1983-05-19 1989-11-09 Unilever Nv Improvements in the expression of newly introduced genes in yeast cells
EP0162854A1 (en) * 1983-11-28 1985-12-04 Vortran Corporation Gas-powered nebulizer
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4940661A (en) * 1984-05-17 1990-07-10 Genentech, Inc. Metallothionein transcription control sequences and use thereof
US4931373A (en) * 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4752576A (en) 1984-06-14 1988-06-21 Chiron Corporation Expression of α-1 antitrypsin in yeast
US4732973A (en) * 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US5013652A (en) * 1986-10-14 1991-05-07 Genex Corporation Composite yeast vectors
US5166134A (en) * 1986-12-24 1992-11-24 John Lezdey Treatment of allergic rhinitis
US5093316A (en) * 1986-12-24 1992-03-03 John Lezdey Treatment of inflammation
US4839283A (en) 1986-12-30 1989-06-13 Zymogenetics, Inc. Method of expressing alpha-1-antitrypsin in yeast
JP2656944B2 (en) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ Aerosolization of protein therapeutics
US4929555A (en) * 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
FR2660509B1 (en) * 1990-03-29 1993-11-19 Alcatel Cit DIFFERENTIAL STAGE OF ELECTRONIC EQUIPMENT OUTPUT.
US5134119A (en) * 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5268384A (en) 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
TW282490B (en) 1992-12-15 1996-08-01 Ciba Geigy Ag
AU671724B2 (en) 1993-03-16 1996-09-05 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as metalloproteinase inhibitors
CA2160139A1 (en) 1993-04-07 1994-10-13 Richard Edward Galardy Synthetic matrix metalloprotease inhibitors and uses thereof
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US6037472A (en) 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
DE69528591T2 (en) 1994-08-05 2003-02-20 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville PRODUCTION OF THE INHIBITOR FOR THE COMPLEX FORMATION OF THE TISSUE FACTOR
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
WO1997042168A1 (en) 1996-05-06 1997-11-13 Zeneca Limited Thio derivatives of hydroxamic acids
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
GB9715962D0 (en) 1996-08-23 1997-10-01 Zeneca Ltd Sulfonamides
US6610683B2 (en) * 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
EP0929517B1 (en) 1996-10-02 2002-06-12 Novartis AG Hydroxamic acid derivatives
AU6843498A (en) 1997-03-28 1998-10-22 Zeneca Limited Process for the preparation of n-(3-hydroxy-succinyl)-amino acid derivatives
FR2762315B1 (en) 1997-04-22 1999-05-28 Logeais Labor Jacques AMINO ACID DERIVATIVES INHIBITOR OF EXTRACELLULAR MATRIX METALLOPROTEASES AND TNF ALPHA RELEASE
EP0911416B1 (en) 1997-10-01 2006-05-17 DSM IP Assets B.V. Protein production process
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
EP1047450B1 (en) * 1997-12-23 2002-10-02 Warner-Lambert Company Ace inhibitor-mmp inhibitor combinations
GB9804504D0 (en) 1998-03-03 1998-04-29 Leo Pharm Prod Ltd Matrix metalloproteinase inhibitors
CZ20012060A3 (en) 1998-12-09 2001-11-14 American Home Products Corporation Thiourea compounds containing acetamide and substituted acetamide, and functioning as inhibitors of herpes viruses
AU3511500A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
JP2002539172A (en) 1999-03-17 2002-11-19 ノバルティス アクチエンゲゼルシャフト Pharmaceutical composition containing TGF-beta
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2387351C (en) 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
CZ20022413A3 (en) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
WO2002053138A2 (en) 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
PA8539301A1 (en) 2001-02-14 2002-09-30 Warner Lambert Co INHIBITORS OF THE METALOPROTEINASE OF THE MATRIX
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US20030211548A1 (en) * 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
WO2003068188A1 (en) 2002-02-18 2003-08-21 University Of Southampton Combination therapy for respiratory disorders
AU2003214108A1 (en) 2002-03-08 2003-09-22 Novartis Ag Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
CA2526222A1 (en) 2003-05-16 2004-12-02 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease associated with matrix metalloprotease inhibitors
US20060205671A1 (en) 2003-07-02 2006-09-14 Jakob Vinten-Johansen Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284044A1 (en) * 1987-03-23 1988-09-28 Zymogenetics, Inc. High level expression in yeast
US6068994A (en) * 1989-08-07 2000-05-30 Chiron Corporation Ubiquitin expression system
WO2002050287A2 (en) * 2000-12-18 2002-06-27 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAMER I MELIH ET AL: "Production and recovery of recombinant protease inhibitor alpha1-antitrypsin", ENZYME AND MICROBIAL TECHNOLOGY, vol. 29, no. 10, 5 December 2001 (2001-12-05), pages 611 - 620, XP002315748, ISSN: 0141-0229 *

Also Published As

Publication number Publication date
US20050084972A1 (en) 2005-04-21
AU2004263900A1 (en) 2005-02-17
US7892825B2 (en) 2011-02-22
US20090042278A1 (en) 2009-02-12
EP1660661A2 (en) 2006-05-31
EP2287326A1 (en) 2011-02-23
US7419801B2 (en) 2008-09-02
WO2005014825A2 (en) 2005-02-17
CA2534352A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
WO2005014825A3 (en) Methods of protein production in yeast
Panda Bioprocessing of therapeutic proteins from the inclusion bodies of Escherichia coli
Fleer et al. Stable multicopy vectors for high–level secretion of recombinant human serum albumin by Kluyveromyces Yeasts
CA2285658A1 (en) Direct expression of peptides into culture media
ATE490309T1 (en) MUTANT E. COLI-APPA PHYTASE ZYMES AND NATURAL VARIANTS THEREOF, NUCLEIC ACIDS ENCODING SUCH PHYTASE ZYMES, VECTORS AND HOST CELLS CONTAINING THE SAME, AND METHODS FOR THE PRODUCTION AND USE THEREOF
CA2180103A1 (en) Gene encoding adseverin
WO2002040679A3 (en) Corynebacterium glutamicum promoters
CA2589951A1 (en) Method for producing carboxy-terminal amidated peptides
WO2002040697A3 (en) Metabolic rate shifts in fermentations expressing recombinant proteins
CN110564708B (en) Recombinant phospholipase D and application thereof in synthesis of phosphatidylserine or other phospholipids
KR100484653B1 (en) Preparation method for the production of active and soluble proteins in prokaryotes and polycistronic vectors therefor
Yim et al. High-level secretory production of human granulocyte-colony stimulating factor by fed-batch culture of recombinant Escherichia coli
AU2003294397A1 (en) Promoter variants for expressing genes in a fungal cell
EP0494702A3 (en) Production of factor xiiia by gene technology
Henikoff Multifunctional polypeptides for purine de novo synthesis
Suzuki et al. Expression, purification, and characterization of authentic mouse prolactin obtained in Escherichia coli periplasmic space
TW493003B (en) Process for producing protein
DE60226592D1 (en) DESOXYCYTIDINKINASE MUTANTS WITH ADVANCED ENZYME ACTIVITY
EA022946B1 (en) Process for obtaining aspart insulin using a pichia pastoris yeast strain
CA3133238A1 (en) Microbial production of compounds
TW200600581A (en) Nucleic acid construct and expression vector for enhancing the production of recombinant protein, and method for the massive production of recombinant protein
Koo et al. Increased production of recombinant protein by Escherichia coli deficient in acetic acid formation
WO2003038035A3 (en) T. reesei phytase enzymes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
CN110872595B (en) Acid-fast expression cassette and its application in fermentation to produce organic acids
CN101157725B (en) Preparation method of human insulin analogue and usage thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2534352

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004263900

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004263900

Country of ref document: AU

Date of ref document: 20040809

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2004780765

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004263900

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004780765

Country of ref document: EP